Skip to content
Markets News
Earnings1 min read

Haleon Cuts Revenue Growth Target After Weak Flu Demand

Makkler Newsroom
October 29, 2026 · Based on reporting by City A.M.

The consumer health group lowered its 2026 revenue growth outlook as cough, cold and flu sales weighed on third-quarter performance.

Key takeaways

  • Haleon cut its revenue growth target to 2.5% from a range of 3% to 5%.
  • Third-quarter organic revenue growth was 2.6%, below the company’s expectations.

Haleon cut its revenue growth target to 2.5% from a previous range of 3% to 5%, citing weak demand for cough, cold and flu medicines. The company said third-quarter organic revenue growth was 2.6%, below expectations.

The slowdown in flu medicine demand reduced North American sales growth to 2.5% from 3.1%. Higher demand for Sensodyne toothpaste provided a brighter spot, while European revenue fell 0.6%, partly due to weak Centrum sales.

Haleon shares fell more than 11% to 333 pence in early trading, according to City A.M. As of Thursday afternoon, they traded at 314.79 pence, down 15.83% since the previous close.

Topics
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.